| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/12/2023 | 313.22% | Maxim Group | $9 → $5 | Maintains | Buy |
| 04/19/2022 | 643.8% | Maxim Group | → $9 | Initiates Coverage On | → Buy |
| 08/03/2021 | 1552.89% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 08/02/2021 | 1552.89% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 10/28/2020 | 891.74% | Craig-Hallum | → $12 | Initiates Coverage On | → Buy |
What is the target price for Processa Pharma (PCSA)?
The latest price target for Processa Pharma (NASDAQ: PCSA) was reported by Maxim Group on January 12, 2023. The analyst firm set a price target for $5.00 expecting PCSA to rise to within 12 months (a possible 313.22% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Processa Pharma (PCSA)?
The latest analyst rating for Processa Pharma (NASDAQ: PCSA) was provided by Maxim Group, and Processa Pharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Processa Pharma (PCSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on January 12, 2023 so you should expect the next rating to be made available sometime around January 12, 2024.
Is the Analyst Rating Processa Pharma (PCSA) correct?
While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a maintained with a price target of $9.00 to $5.00. The current price Processa Pharma (PCSA) is trading at is $1.21, which is out of the analyst's predicted range.